Crucial Points from a Manufacturing Perspective (PDA/FDA Joint Regulatory Conference 2023)
October 17th 2023Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the important components of nitrosamine impurities from a manufacturing point of view as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."
The Recent Discoveries of Nitrosamine Impurities (PDA/FDA Joint Regulatory Conference 2023)
October 16th 2023Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the recent findings of nitrosamine impurities in human drugs as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."
The Challenges of the Journey from Clinical to Commercial Cell Therapies
October 12th 2023Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the journey from clinical to commercial cell therapies as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."